A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies투과성 연구에서 나노제형을 사용하여 적용된 COVID-19 약물 몰누피라비르의 측정을 위한 안정성을 나타내는 RP-HPLC 방법Article Published on 2022-05-302022-09-11 Journal: Journal of pharmaceutical and biomedical analysis [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 antiviral drugs applied Caco-2 calculated candidate cell line column conditions Coronavirus-2 Council COVID-19 demonstrated drug drug candidate drug delivery system flow rate homogeneity ICH in vitro Infection linear molnupiravir N4-hydroxycytidine nucleoside optimization oxidative stress pandemic peak permeability prodrug quantitation robust RP-HPLC SARS-CoV-2 SARS-CoV-2 treatment selective Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus specificity stability validation was performed was used water [DOI] 10.1016/j.jpba.2022.114693 PMC 바로가기 [Article Type] Article
A Nanopore Based Molnupiravir SensorArticle Published on 2022-05-272023-07-08 Journal: ACS Sensors [Category] COVID19(2023년), [키워드] molnupiravir Mycobacterium smegmatis porin A Nucleoside analogues programmable nanoreactors single-molecule chemistry. [DOI] 10.1021/acssensors.2c00447
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In VivoMolnupiravir 및 활성 형태인 EIDD-1931, 시험관 내 및 생체 내 엔테로바이러스 감염에 대한 강력한 항바이러스 활성을 나타냄Article Published on 2022-05-252022-09-11 Journal: Viruses [Category] 치료제, [키워드] active form activity administration Analysis Antiviral antiviral drug approved aseptic meningitis children Concentration concentrations COVID-19 death disease drug candidate EIDD-1931 EIDD-2801 Encephalitis enterovirus expression foot form hand Health authority indicated Infant Infants Infection infections mechanism Meningitis mice molnupiravir myocarditis plasma drug potent progeny reduce reducing reported show significantly state Treatment treatment of COVID-19 United Kingdom various tissue various tissues Viral load Viral protein virus [DOI] 10.3390/v14061142 PMC 바로가기 [Article Type] Article
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 Research Published on 2022-05-162022-10-05 Journal: Nature [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] addition Antiviral Antiviral compound antiviral drug B.1.1.529 characterization chimeric COVID-19 delta variant dominant effective Effectiveness evaluated expressing hamster hamsters individual isolate less Lineage mice molnupiravir monoclonal antibody Mutation Neutralizing activity omicron organ pathogenicity plasma raised recipient reduction in REGN10933 REGN10987 Replication replicative restrict rodent S309 SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 strains Strains susceptibility the spike protein therapeutic Vaccine Vaccines variant variants viral infection [DOI] 10.1038/s41586-022-04856-1 [Article Type] Research
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?COVID-19와 소분자 치료제의 약속: 배워야 할 교훈이 있습니까?Review Published on 2022-05-012022-09-11 Journal: Pharmacological research [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant therapy Antiviral antiviral agent Antiviral agents antivirals Baricitinib Baricitinib (PubChem CID: 44205240) Chloroquine Chloroquine (PubChem CID: 2719) coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical developmental Dexamethasone Dexamethasone (PubChem CID: 5743) drug Drug discovery effective Endemic Healthcare professional healthcare professionals Hydroxychloroquine Hydroxychloroquine (PubChem CID: 3652) Inclusion Ivermectin Ivermectin (PubChem CID: 6321424) limitation Lopinavir Lopinavir (PubChem CID: 92727) molnupiravir Molnupiravir (Pubchem CID: 145996610) Nirmatrelvir Nirmatrelvir (PubChem CID: 155903259) pandemic provided PubChem Remdesivir Remdesivir (PubChem CID: 121304016) researcher Retrospective analysis Ritonavir Ritonavir (PubChem CID: 392622) SARS-CoV-2 severe acute respiratory syndrome Coronavirus small molecule Small molecule therapeutics. standstill tested the disease therapy Treatment treatment of COVID-19 while with COVID-19 [DOI] 10.1016/j.phrs.2022.106201 PMC 바로가기 [Article Type] Review
Can Panax ginseng help control cytokine storm in COVID-19?Review article Published on 2022-05-012022-10-05 Journal: Journal of Ginseng Research [Category] 치료제, [키워드] activities acute respiratory syndrome antiviral drug approach article Can cascade caused conditions coronavirus Coronavirus disease 2019 COVID-19 cytokine production Cytokine storm drug Effect Effectiveness Efficiency Evidence help induce innate immune response medication Mild Moderate COVID-19 molnupiravir Panax ginseng pandemic Paxlovid positive pro-inflammatory cytokine Ritonavir SARS-CoV-2 SARS-CoV-2 variants searched Side effects Therapeutic strategies treat Treatment [DOI] 10.1016/j.jgr.2022.02.006 [Article Type] Review article
Concise synthesis of antiviral drug, molnupiravir by direct coupling of fully protected d-Ribose with cytosineShort communication Published on 2022-05-012022-10-05 Journal: Tetrahedron Letters [Category] 치료제, [키워드] Anti-viral antiviral drug cytidine cytosine d-Ribose effective expand expected group groups hydrolysis hydroxy less molnupiravir Ribonucleoside uridine [DOI] 10.1016/j.tetlet.2022.153783 [Article Type] Short communication
Molnupiravir; molecular and functional descriptors of mitochondrial safety몰누피라비르; 미토콘드리아 안전성의 분자 및 기능 설명자Article Published on 2022-05-012022-09-11 Journal: Toxicology and applied pharmacology [Category] COVID19(2023년), SARS, 유전자 메커니즘, 치료제, [키워드] active form Adult patients Analyzer antiviral drug antiviral drugs approved arrest cell line Concentration concentrations copy number COVID-19 Culture cytotoxicity DNA polymerase dose drug emergency treatment Endpoint expression flux functional Genome HepG2 HepG2 cell incorporation inhibit lack mechanism metabolite Mitochondria mitochondrial mitochondrial DNA Mitochondrial function mitochondrial gene molecular molnupiravir Mutation N-hydroxycytidine NHC nucleoside Patient phenotypic PolG POLRMT progression RdRP replicating virus Replication resulting risk RNA polymerase significantly specificity the SARS-CoV-2 Toxicity Transcription Treatment triphosphate U.S. FDA viral genome virus was measured [DOI] 10.1016/j.taap.2022.116003 PMC 바로가기 [Article Type] Article
The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic reviewResearch article Published on 2022-05-012022-10-05 Journal: Saudi Pharmaceutical Journal : SPJ [Category] 변종, 신약개발, 임상, 치료법, 치료제, [키워드] acting addition administration Anti-viral antiviral agent article bioRxiv clinical Clinical studies clinical trials COVID COVID-19 CTRI cumulative disease duplicate effective EIDD-1931 EIDD-2807 Emergency use authorization Evidence excluded exhibiting FDA global pandemic Hospitalization initial search ISRCTN limit manual medRxiv Mild MK-4482 moderate Moderate COVID-19 molnupiravir Mortality NHC NIH Patient performed progression Prophylactic reduction in Repurposing anti-viral drugs Result risk factor SARS-CoV-2 virus Science Direct shown systematic review the disease therapy treat Treatment Trial Vaccine virus spread virus titer were used [DOI] 10.1016/j.jsps.2022.03.002 [Article Type] Research article
Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic ActivityReview Published on 2022-04-182023-07-01 Journal: Viruses [Category] COVID19(2023년), SARS, [키워드] error catastrophe Favipiravir HIV lethal mutagenesis molnupiravir nucleoside analogs ribavirin RNA polymerase SARS-CoV-2 [DOI] 10.3390/v14040841 PMC 바로가기 [Article Type] Review